Multiplexed same type-antigenic peptide

Patent metadata

Field	Value
Publication number	US-10428112-B2
Application number	US-201515317693-A
Country	US
Kind code	B2
Filing date	Jun 11, 2015
Priority date	Jun 11, 2014
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.

First claim

The invention claimed is:

1. A multiplexed same type-antigenic peptide comprising a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type, which are bound to the terminal ends of the dendritic core directly or via a spacer, and production of a class-switched antibody is induced by directly stimulating B cells in vivo in the absence of a T cell epitope; wherein the dendritic core has the following structure:

2. The multiplexed same type-antigenic peptide according to claim 1 , wherein the B-cell recognition peptide is a peptide consisting of 7 to 50 amino acid residues.

3. The multiplexed same type-antigenic peptide according to claim 1 , wherein the B-cell recognition peptide is an autoantigen.

4. The multiplexed same type-antigenic peptide according to claim 3 , wherein the autoantigen is an antigen from IgE.

5. An antibody production-inducing agent comprising the multiplexed same type-antigenic peptide according to claim 1 , as an active ingredient.

6. The antibody production-inducing agent according to claim 4 , further comprising interferon γ and/or an adjuvant having an ability to produce interferon γ.

7. The antibody production-inducing agent according to claim 4 , wherein the antibody is an IgG antibody.

8. The antibody production-inducing agent according to claim 4 , wherein the antibody production-inducing agent is a vaccine.

9. A pharmaceutical composition comprising the antibody production-inducing agent according to claim 4 .

10. A method for producing the multiplexed same type-antigenic peptide according to claim 1 , comprising:
(a) providing a dendritic core having reactive functional groups;
(b) providing a plurality of B-cell recognition peptides of the same type having reactive functional groups;
(c) effecting a binding reaction of the reactive functional group of the dendritic core with the reactive functional group of each B-cell recognition peptide to prepare the multiplexed antigenic peptide; and
(d) collecting the multiplexed antigenic peptide.

Assignees

• Riken
• Animal Allergy Clinical Laboratories Inc
• Nippon Zenyaku Kogyo Co Ltd

Inventors

• Masuda Kenichi
• Ishii Yasuyuki
• Tsukui Toshihiro

Classifications

• C07K17/02

  Peptides being immobilised on, or in, an organic carrier · CPC title

• C07K16/42

  against immunoglobulins · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K2039/55522

  Cytokines; Lymphokines; Interferons · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title